Nicox S.A. (OTCMKTS:NICXF – Free Report) – Research analysts at HC Wainwright cut their Q4 2024 EPS estimates for Nicox in a note issued to investors on Tuesday, April 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.06) per share for the quarter, down from their prior forecast of ($0.05). The consensus estimate for Nicox’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Nicox’s Q1 2024 earnings at ($0.03) EPS, Q2 2024 earnings at ($0.09) EPS, Q3 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.26) EPS.
Nicox Price Performance
OTCMKTS:NICXF opened at $0.44 on Thursday. The firm’s 50-day moving average price is $0.44 and its 200-day moving average price is $0.52. Nicox has a 1-year low of $0.44 and a 1-year high of $0.44.
About Nicox
Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
See Also
- Five stocks we like better than Nicox
- How to Invest in Small Cap Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- The How and Why of Investing in Gold Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Dividend Capture Strategy: What You Need to Know
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
